Senores Pharma: Vinay Mishra Relieved as Company Secretary June 10
Senores Pharmaceuticals Limited confirms Mr. Vinay Kumar Mishra's departure as Company Secretary and Compliance Officer, effective June 10, 2026. Mr. Swapnil Jatinbhai Shah and Mr. Deval Rajnikant Shah are now authorized for disclosures. This follows his resignation intimation on May 14, 2026.
The departure of a Company Secretary and the appointment of authorized personnel for disclosures are routine administrative and compliance-related events that typically have a minimal impact on the company's operations or stock price.
The announcement is a routine update regarding the departure of a Company Secretary and the authorization of new personnel for disclosures, which is a standard corporate compliance procedure. It does not contain any positive or negative financial or operational news.
Senores Pharmaceuticals Limited has announced that Mr. Vinay Kumar Mishra will be relieved from his duties as Company Secretary and Compliance Officer, effective from the close of business hours on June 10, 2026. This follows the company's earlier intimation on May 14, 2026, regarding his resignation.
In accordance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has authorized key managerial personnel to determine the materiality of events and make disclosures. The authorized individuals are Mr. Swapnil Jatinbhai Shah, Managing Director, and Mr. Deval Rajnikant Shah, Whole Time Director and Chief Financial Officer. Their contact details for such disclosures have been provided.
The company has already submitted the requisite information as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, along with Mr. Mishra's resignation letter, in their previous intimation on May 14, 2026.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.